# OnCo record egle-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/egle-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "egle-therapeutics" ;
  schema:name "Egle Therapeutics"@en ;
  schema:alternateName "Egle Therapeutics SAS"@en ;
  schema:description "Egle Therapeutics is a Paris company developing medicines that act on regulatory T cells, the immune cells that can shield a tumour from attack. Its cancer drug, EGL-001, is designed to selectively inhibit these cells inside tumours and is in an early trial in advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/egle-therapeutics/>, <https://www.egle-tx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.egle-tx.com/>, <https://www.egle-tx.com/egle-therapeutics-strengthens-its-executive-leadership-team-with-the-appointment-of-christophe-queva-ph-d-as-chief-executive-officer/>, <https://clinicaltrials.gov/study/NCT06622486> ;
  schema:addressCountry "FR" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/immunocytokines/> ;
  onco:targets <https://onco.cc/targets/ctla4/> ;
  onco:trials <https://onco.cc/trials/nct06622486/> .